Main Events and hot topics
Don’t miss all of the exciting new science at #ISC26.
Opening Main Event
11 a.m.-12:30 p.m. | Wednesday, Feb. 4 | Main Event 1
- The Chemical Optimization of Cerebral Embolectomy (CHOICE2) Trial: Main Results
- Recombinant Factor VIIa for Spontaneous Intracerebral Hemorrhage Within Two Hours of Onset. The FASTEST Trial
- The Effect of Treatment on Cognitive Function in Patients With Asymptomatic Carotid Artery Stenosis: The CREST-2 Trial
Thursday’s Main Event
11 a.m.-12:30 p.m. | Thursday, Feb. 5 | Main Event 2
- Factor XIa Inhibition With Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial
- Tenecteplase for Acute Nonlarge Vessel Occlusion at 4.5-24 Hours
- Intravenous Tenecteplase Plus Endovascular Thrombectomy vs. Endovascular Thrombectomy Alone on 4.5 to 24 Hours After Stroke Due to Basilar Artery Occlusion: A Multicenter Randomized Controlled, Clinical Trial (ATTENTION LATE)
- Endovascular Treatment With or Without Preceding Intravenous Tenecteplase in Patients With Late-Window Acute Ischemic Stroke Due to Middle Cerebral Artery Occlusion (TNK-PLUS): A Multicenter Prospective Open-Label, Blinded Endpoint, Phase 3, Randomized Controlled Trial
- The EMBOLISE Study: Embolization of the Middle Meningeal Artery With ONYXTM Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma
- Tirofiban for Branch Atheromatous Disease-Related Stroke: A Randomized Double-Blind, Placebo-Controlled Trial
Closing Main Event
11 a.m.-1:25 p.m. | Friday, Feb. 6 | Main Event 3
- Final Results of the SPAN2 Trial
- The I-ACQUIRE Trial of Constraint Induced Movement Therapy for Infants/Toddlers With Perinatal Arterial Ischemic Stroke
- Loberamisal for Acute Ischaemic Stroke (LAIS): A Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase 3 Clinical Trial
- LT3001 Improves Functional Outcomes in Disabling Acute Ischemic Stroke: Results From Two Phase 2 Trials
- Efficacy and Safety of Chuanzhi Tongluo Capsule for Acute Ischemic Stroke Patients Without Large or Medium-Sized Vessel Occlusion (CONCERN): A Multicenter Double-Blind Randomized Control Trial
- Endovascular Treatment of Medium Vessel Occlusion Strokes With Moderate or Higher Clinical Severity
- Primary Results of the DISTALS (Distal Ischemic Stroke Treatment With Adjustable Low-Profile Stentriever) Randomized Trial of TIGERTRIEVER 13-EVT for DMVO
- A Randomized Trial of an At-Home Brain Computer Interface Therapy Compared To Standard Exercise Therapy For Chronic Upper Extremity Motor Deficit After Stroke
Late-Breaking Science Oral Abstracts I
5-6 p.m. | Wednesday, Feb. 4 | Room 220-222
· Annual Stroke Risk for Medical Management Patients With High-Grade Carotid Stenosis: CREST-2 With Comparisons to SPACE-2 and ECST-2
· Efficacy and Safety of a Patch-Type Cardiac Monitor for Diagnosing Paroxysmal Atrial Fibrillation in Embolic Stroke of Undetermined Source Patients With Left Atrial Enlargement (SOLO-ESUS): A Randomized Controlled Trial
· MIRACLE: Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients With Acute Ischemic Stroke With Large Infarct: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
· Anti-Inflammatory Mechanisms of Anti-Sdc2 Mab VB-001 Contributing to Neuroprotection After Ischemic Stroke
· Development and Evaluation of Anti-Matrix Metalloproteinase-12 Single-Chain Variable Fragment Antibodies as Potential Therapeutics for Ischemic Stroke
Late-Breaking Science Oral Abstracts II
2:30-3:30 p.m. | Thursday, Feb. 5 | Room 206-207
· Factors Associated With Sex Differences in Cognitive Decline: A Pooled Cohort Analysis of ARIC, CHS, FOS, MESA and CARDIA in the BP COG Study
· Normal Saline Infusion for Stroke After Intravenous Thrombolysis: A Randomized Multicenter Trial
· The MLC1501 Study Assessing Efficacy in Post-STrOke Subjects with MOtor Deficits (MAESTOSO)
· Time Effects of Long-Term BP Lowering After Intracerebral Hemorrhage: Pooling of Individual Patient Data From Progress, Respect, Espirit and Trident Trials
· EMMA-Can: A Three-Arm Study Comparing Prospective Registry and Randomized Trial Designs for Middle Meningeal Artery Embolization in Chronic Subdural Hematoma
Beyond the Plenary: Deeper Dives Into OCEANIC-STROKE, CREST-2 and FASTEST (Late-Breaking Science Oral Abstracts III)
3:45-4:45 p.m. | Thursday, Feb. 5 | Hall D, Main Event Hall
· Qualifying Ischemic Stroke Subtypes and Response to Asundexian: Prespecified Secondary Analysis of the OCEANIC-STROKE Trial
· Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis – Hemodynamics – Main Results
· Assessment of the Potential for Stroke Risk Reduction Following Carotid Revascularization to Extend Beyond Four Years: CREST-2
· Recombinant Factor VIIa Treatment Within Two Hours of Spontaneous Intracerebral Hemorrhage Onset Decreases Hematoma Expansion and Improves 90-Day Outcomes in CT Angiography Spot Sign – Positive Patients
· Exploring the Optimal Time Window for Treatment With Recombinant Activated Factor VII (rFVIIa) in Patients With Intracerebral Hemorrhage
Late-Breaking Science Oral Abstracts IV
5-6 p.m. | Thursday, Feb. 5 | Room 206-207
· Propranolol for Prevention of Stroke-Associated Pneumonia in Intracerebral Hemorrhage (PROCHASE): A Multicenter, Randomized, End Point Blind Trial
· ARPEGGIO Phase 2 Trial of Scp776, a First-in-Class Cerebroprotective Agent in Patients Undergoing Endovascular Thrombectomy: Pre-Specified Efficacy Analyses
· Sublingual Cilostazol and Dexborneol for the Treatment of Acute Ischemic Stroke: A Randomized Clinical Trial
· Safety and Efficacy of Adjunctive Intra-Arterial Adenosine Following Successful Endovascular Thrombectomy in Patients With Large Vessel Occlusion Acute Ischemic Stroke (REACT) Trail
· Early vs. Late Time Window Tenecteplase for Basilar Artery Occlusion, With or Without Thrombectomy: A Subgroup Analysis From the TRACE-5 Trial
And don’t miss the Late-Breaking Science Poster Session
12:30-2:30 p.m. | Wednesday, Feb. 4 | Hall B, Poster Hall
